Client Login
Pay My Bill
Services
Adherence Monitoring
Pain Management
Mental Illness
Substance Use Disorder
Chronic Comorbidities
BioDetect
Novel Psychoactive Substances
InterACT Rx
Sports Testing
Clinical Blood Testing
Infectious Disease Testing
Clinical Resources
About Definitive Testing
Clinical Updates
Webinars
Events
Patient Impact Stories
Publications
Reference Guide
Collection Instructions
Work With Us
Current Openings
About
The Aegis Difference
Executive Leadership
Clinical and Scientific Team
Testimonials
Lab Tour
News
Contact
Client Login
Pay My Bill
Services
Adherence Monitoring
Pain Management
Mental Illness
Substance Use Disorder
Chronic Comorbidities
BioDetect
Novel Psychoactive Substances
InterACT Rx
Sports Testing
Clinical Blood Testing
Infectious Disease Testing
Clinical Resources
About Definitive Testing
Clinical Updates
Webinars
Events
Patient Impact Stories
Publications
Reference Guide
Collection Instructions
Work With Us
Current Openings
About
The Aegis Difference
Executive Leadership
Clinical and Scientific Team
Testimonials
Lab Tour
News
Contact
Client Login
Pay My Bill
News
Aegis Sciences Corporation Provides Insights into Early Detection Methods of COVID-19 Variants
Aegis Sciences Corporation Expands Testing for Novel Psychoactive Substances
Aegis Sciences Corporation Now Performs Monkeypox Testing
Aegis Sciences Corporation Designated as a UnitedHealthcare Preferred Lab Network Provider
Aegis adopts genotyping approach to track SARS-CoV-2 variants through NIH funded project
Citing Data Shared by Aegis Sciences, CDC Releases Publication Finding
2
3
4
5
6
7
8
Sign up for the Aegis Newsletter
Δ
Close